about
Use of thiopurines in inflammatory bowel disease: Safety issues.The differential effect of NAT2 variant alleles permits refinement in phenotype inference and identifies a very slow acetylation genotypeSuperoxide Dismutase Gene (SOD1, SOD2, and SOD3) Polymorphisms and Antituberculosis Drug-induced Hepatitis.Trends in qualifying biomarkers in drug safety. Consensus of the 2011 meeting of the spanish society of clinical pharmacologyRecent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.FCERI and Histamine Metabolism Gene Variability in Selective Responders to NSAIDSOxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicityPredicting and preventing acute drug-induced liver injury: what's new in 2010?Assessment of nonsteroidal anti-inflammatory drug-induced hepatotoxicity.The primary role of hepatic metabolism in idiosyncratic drug-induced liver injury.Genetic risk factors for drug-induced liver injury in rheumatoid arthritis patients using low-dose methotrexate.Utilization of glutathione S-transferase Mu 1- and Theta 1-null mice as animal models for absorption, distribution, metabolism, excretion and toxicity studies.Anti-Parkinson's disease drugs and pharmacogenetic considerations.Female gender as a susceptibility factor for drug-induced liver injury.Key factors of susceptibility to anti-tuberculosis drug-induced hepatotoxicity.Adverse Outcome Pathways and Drug-Induced Liver Injury Testing.Development of HepG2-derived cells expressing cytochrome P450s for assessing metabolism-associated drug-induced liver toxicity.NAT2 polymorphisms and risk for Parkinson's disease: a systematic review and meta-analysis.Chronic and low exposure to a pharmaceutical cocktail induces mitochondrial dysfunction in liver and hyperglycemia: Differential responses between lean and obese mice.Icodextrin-associated hepatotoxicity.Association study of UGT1A9 promoter polymorphisms with DILI based on systematically regional variation screen in Chinese population.Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury.
P2860
Q33621267-A4D83FA3-CA07-4A48-AE5E-03930250A128Q34412637-0C987CCD-6985-4B1D-916F-D825C460F8E1Q34760618-D77222FF-5A4D-4121-96B9-D69558AF59EAQ35681250-FE980DE2-3BCE-49A9-9B08-993D3EB9D487Q37121662-64E19E6A-FD5D-4C0B-AD8C-1E91866F9368Q37293225-4B8147E4-D294-4467-823B-06123E0C8EA0Q37656707-6CEC7131-7470-4344-A7D2-0E44ED64D589Q37771029-B5A6CFAE-B734-4DAB-9165-503D13D771BDQ37862739-57DA883C-084B-4C32-96FD-5B68BAE5280CQ37979858-4957B7E8-643F-424C-B452-FA447C749CC8Q38068540-987E0BFA-1D51-4370-BC0B-28BD37D126F4Q38090712-78656580-A211-4F7B-B66A-6D6B8BEF057CQ38097097-0A27DAAF-2FCC-42D8-8FC1-4B41F45A0566Q38168331-219C2B0B-C7E3-466F-881B-7202653B3C15Q38360770-AD7EA6AC-C19A-4325-9541-9159A754DA25Q38539524-D80ACF72-76D5-4E78-8877-C05F17EB0C51Q38827021-8646B89C-C481-4745-8589-FE9B99210EA4Q38842411-FDEA54E8-8199-4338-BCD2-FFB398432F38Q39512563-1872DE80-6BC2-4A3A-8DB3-CA161F1590C8Q40329355-67B7120F-7746-416F-96B5-1DB876C2B2F5Q41636182-8DF80854-B91F-4FB3-915A-56ADD30765AEQ43005717-9EFEB392-477B-44C1-962A-24469BF21CC4
P2860
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Pharmacogenomics in drug induced liver injury.
@en
Pharmacogenomics in drug induced liver injury.
@nl
type
label
Pharmacogenomics in drug induced liver injury.
@en
Pharmacogenomics in drug induced liver injury.
@nl
prefLabel
Pharmacogenomics in drug induced liver injury.
@en
Pharmacogenomics in drug induced liver injury.
@nl
P2093
P1476
Pharmacogenomics in drug induced liver injury.
@en
P2093
Carmen Martínez
José A G Agúndez
M Isabel Lucena
Raquel Cueto
Raúl J Andrade
P304
P356
10.2174/138920009790711805
P407
P577
2009-11-01T00:00:00Z